[at Forbes] – In terms of therapeutic areas, we expect cancer drugs to do well, as the pressure on cardiovascular sales continues. Geographically speaking, emerging markets will be in focus due to the expected volume growth driven by sales of Prevenar.
Read more on this.
Pfizer Inc. (PFE), with a current market cap of $200.98B, opened at $31.02.
Today, shares have traded between $30.91 and $31.23 per share with the price of the stock fluctuating between $26.76 to $32.50 over the last 52 weeks.
Pfizer (PFE) shares are currently priced at 14.34x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.18x earnings multiple for the same period.
And for passive income investors, the company pays shareholders $1.04 per share annually in dividends, yielding 3.30%.
In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.52 per share, which would be $0.05 better than the year-ago quarter and a $0.01 sequential decrease. The full-year EPS estimate is $2.18, which would be a $0.01 better than last year.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $13.35 Billion. If reported, that would be a 11.41% decrease over the year-ago quarter.
More recently, Standpoint Research downgraded PFE from Hold to Sell (Jul 2, 2013). Previously, MKM Partners downgraded PFE from Buy to Neutral.
When considering if the stock is under or overvalued, the average price target is $33.19, which is 7.00% above where the stock opened this morning.
Pfizer Inc (NYSE:PFE), a biopharmaceutical company, discovers, develops, manufactures and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians.
Tag Helper ~ Stock Code: PFE | Common Company name: Pfizer | Full Company name: Pfizer Inc (NYSE:PFE) .